Atty. Docket No.:

20200/2052

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Wajant, et al.

Serial No.:

10/666,458

Filed:

September 19, 2003

Entitled:

COMPOSITIONS AND METHODS

FOR TREATING TRAIL-

RESISTANT CANCER CELLS

Examiner:

Not Yet Assigned

Group Art Unit:

Not Yet Assigned

Conf. No.:

Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda M. Woods

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date:

December 9, 2003

Respectfully submitted,

Name: Barbara A. Gyure & Registration No.: 34,614 Palmer & Dodge LLP 111 Huntington Avenue Boston, MA 02199-7613

Barbaral - Denne

Tel: 617-239-0100

USPTO Form 1449 Patent and Trademark Office INFORMATION DISCROSURE STATEMENT			Attorney Docket No. 20200/2052			Serial No. 10/666,458		
		5		Applicant(s):. Wajar	nt, et al.			
DEC 2 2 2003 &			Filing Date: September 19, 2003			Group: Not Yet Assigned		
U.S. PA	TENT	OCHMENTS						
Examiner Initial	Patent No.		Date	Name	Class	Subclass	Filing Date (if appropriate)	
	1.	2003/0198627 A1	Oct. 23, 2003	Arts, et al.	424	93.21	Aug. 23	, 2002
	2.	2003/0190635 A1	Oct. 9, 2003	McSwiggen	435	6	Jul. 25,	2002
	3.	2003/0180756 A1	Sep. 25, 2003	Shi, et al.	435	6	Nov. 21.	, 2002
	4.	2003/0176671 A1	Sep. 18, 2003	Reed, et al.	536	23.1	Feb. 7, 2	2002
•	5.	2003/0157030 A1	Aug. 21, 2003	Davis, et al.	424	46	Nov. 4, 2	2002
<i>y</i>	6.	2003/0148341 A1	Aug. 7, 2003	Sin, et al.	435	6	Nov. 5, 2	2002
	7.	2003/0143732 A1	Jul. 31, 2003	Fosnaugh, et al.	435	325	Aug. 20,	2002
	8.	2003/0125281 A1	Jul. 3, 2003	Lewis, et al.	514	44	May 28,	2002
	9.	2003/0108923 A1	Jun. 12, 2003	Tuschl, et al.	435	6	Sep. 26,	
	10.	2002/0086356 A1	Jul. 4, 2002	Tuschl, et al.	435	69.1	Mar. 30,	
	11.	6,423,489 B1	Jul. 23, 2002	Anderson, et al.	435	6	May 30,	
FOREIGN	PATE	NT DOCUMENTS						
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
	12.	DE 101 00 586 C1	April 11, 2002	Deutschland (Germany)	C12N	15/11	YES	NO X
	13.	WO 03/080807 A2	Oct. 2, 2003	PCT	C12N		X	
	14.	WO 03/080794 A2	Oct. 2, 2003	PCT	C12N		X	
	15.	WO 03/074654 A2	Sep. 12, 2003	PCT	C12N		X	
	16.	WO 03/070972 A2	Aug. 28, 2003	PCT	C12		X	
	17.	WO 03/070969 A2	Aug. 28, 2003	PCT	C12Q	A = = = 10	X	
	19.	WO 03/070750 A2	Aug. 28, 2003	PCT	C07K		X	
	19.	WO 03/070283 A2	Aug. 28, 2003	PCT	A61K	48/00	X	
	20.	WO 03/016572 A1	Feb. 27, 2003	PCT	C12Q	1/68	X	
	21.	WO 03/012052 A2	Feb. 13, 2003	PCT	C12N	2,55	X	
	22.	WO 02/068637 A2	Sep. 6, 2002	PCT	C12N	15/11	X	
	23.	WO 02/068635 A2	Sep. 6, 2002	PCT	C12N	15/11	X	

				T				
	24.	WO 02/44321 A2	Jun. 6, 2002	PCT	C12N		X	
	25.	WO 02/26780 A2	Apr. 4, 2002	PCT	C07K	14/00	X	
	26.	WO 01/75164 A2	Oct. 11, 2001	PCT	C12Q	1/68	X	
	27.	WO 00/68374	Nov. 16, 2000	PCT	C12N	15/11	X	
	28.	WO 00/44914	Aug. 3, 2000	PCT	C12N	15/63	X	
	29.	WO 00/44895	Aug. 3, 2000	PCT	C12N	15/11		X
	30.	WO 99/61631	Dec. 2, 1999	PCT	C12N	15/63	X	
	31.	WO 99/53050	Oct. 21, 1999	PCT	C12N	15/11	X	
	32.	WO 99/32619	July 1, 1999	PCT	C12N	15/11	X	
OTHER	DOCUM	ENTS (including Auth	or, Title, Date, Perti	nent Pages, etc.)				
	33.	Holen, T. et al., (2002), "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor", <i>Nucleic Acids Research</i> , 30(8):1757-1766.						
	34.	Ambros, V., (2001), "Dicing Up RNAs", Science, 293:811-813.						
•	35.	Elbashir, S.M. et al., (2001), "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", <i>Nature</i> , 411:494-498.						
	36.	Gautschi, O. et al., (2001), "Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins", <i>Journal of the National Cancer Institute</i> , 93(6):463-471.						
	37.	Lipardi, C. et al., (2001), "RNAi as Random Degradative PCR: siRNA Primers Convert mRNA into dsRNAs that Are Degraded to Generate New siRNAs", Cell, 107:297-307.						
	38.	Sharp, P.A., (2001), "RNA interference – 2001", Genes & Development, 15:485-490.						
	39.	Sijen, T. et al., (2001), "On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing", Cell, 107:465-476.						
	40.	Bass, B.L., (2000), "Double-Stranded RNA as a Template for Gene Silencing", Cell, 101:235-238.						
	41.	Cobaleda, C. et al., (2000), "In vivo inhibition by a site-specific catalytic RNA subunit of Rnase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment", <i>Blood</i> , 95(3):731-737.						
	42.	Hammond, S.M. et al., (2000), "An RNA-directed nuclease mediates post-transcriptional gene silencing in <i>Drosophila</i> cells", <i>Nature</i> , 404:293-296.						
	43.	Yang, D. et al., (2000), "Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in <i>Drosophila</i> embryos", <i>Current Biology</i> , 10:1191-1200.						
	44.	Wianny, F. et al., (2000), "Specific interference with gene function by double-stranded RNA in early mouse development", <i>Nature Cell Biology</i> , 2:70-75.						
	45.	Zamore, P.D. et al., (2000), "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals", <i>Cell</i> , 101:25-33.						
	46.	Fire, A., (1999), "RNA-triggered gene silencing", <i>TIG</i> , 15(9):358-363.						
	47.	Tuschl, T. et al., (1999), "Targeted mRNA degradation by double-stranded RNA in vitro", Genes & Development, 13:3191-3197.						

	48.	Wild, K. et al., (1999), "The 2 Å structure of helix 6 of the human signal recognition particle RNA", Structure, 7(11):1345-1352.				
	49.	Montgomery, M.K. et al., (1998), "Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression", <i>TIG</i> , 14(7):255-258.				
	50.	Lowy, D.R. et al., (1993), "Function and Regulation of RAS", Annu. Rev. Biochem., 62:851-891.				
	51.	Downward, J. et al., (1990), "Identification of a nucleotide exchange-promoting activity for p21 ^{ras} ", <i>Proc. Natl. Acad. Sci. USA</i> ", 87:5998-6002.				
	52.	Gibbs, J.B. et al., (1988), "Purification of ras GTPase activating protein from bovine brain", <i>Proc. Natl. Acad. Sci. USA</i> ", 85:5026-5030.				
	53.	International Search Report of International Application No. PCT/EP02/00151.				
EXAMINER			DATE CONSIDERED			
*EXAMINE	R: Initial if refere	ence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in	Conformance and not considered. Include copy of this form with			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

^{**}Copies of references not provided at the time of this submission.